Gregg Fine
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 25
- Cancer Immunotherapy and Biomarkers 20
- CAR-T cell therapy research 5
-
- Lymphoma Diagnosis and Treatment 5
- Co-authors
- Daniel S. ChenPriti S. HegdeThomas PowlesHoward A. BurrisXiaodong ShenZachary BoydFadi S. BraitehYohann Loriot
- Journals
- Journal of Clinical Oncology (10 papers)Blood (3 papers)Cancer Research (3 papers)Annals of Oncology (2 papers)The Journal of Immunology (2 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Gregg Fine
33 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Oncology 2.8k
- Immunology 1.5k
- Pulmonary and Respiratory Medicine 894
- Cancer Research 386
- Pathology and Forensic Medicine 432
Countries citing papers authored by Gregg Fine
This map shows the geographic impact of Gregg Fine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregg Fine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregg Fine more than expected).
Fields of papers citing papers by Gregg Fine
This network shows the impact of papers produced by Gregg Fine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregg Fine. The network helps show where Gregg Fine may publish in the future.
Co-authors
The 25 scholars most cited alongside Gregg Fine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 242 | |
| 2 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study Hit paper breakdown → | 2016 | 409 |
| 3 | 2016 | 11 | |
| 4 | 2016 | 9 | |
| 5 | 2015 | 10 | |
| 6 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Hit paper breakdown → | 2014 | 1850 |
| 7 | 2014 | 1 | |
| 8 | 2014 | 7 | |
| 9 | 2013 | 11 | |
| 10 | 2013 | 157 | |
| 11 | 2013 | 7 | |
| 12 | 2013 | 84 | |
| 13 | 2012 | 117 | |
| 14 | 2011 | 1 | |
| 15 | 2011 | 33 | |
| 16 | 2008 | 20 | |
| 17 | 2008 | 1 | |
| 18 | 1998 | 45 | |
| 19 | 1996 | 88 | |
| 20 | 1951 | 7 |
About Gregg Fine
Gregg Fine is a scholar working on Oncology, Pathology and Forensic Medicine, Immunology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 33 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (20 papers), Bladder and Urothelial Cancer Treatments (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Immunotherapy and Immune Responses (4 papers), Renal cell carcinoma treatment (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Oncology (2.8k citations), Immunology (1.5k citations), Pulmonary and Respiratory Medicine (894 citations), Cancer Research (386 citations) and Pathology and Forensic Medicine (432 citations). Gregg Fine has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Daniel S. Chen, Priti S. Hegde, Thomas Powles, Howard A. Burris, Xiaodong Shen, Zachary Boyd, Fadi S. Braiteh, Yohann Loriot, Daniel P. Petrylak and Nicholas J. Vogelzang. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Research, Annals of Oncology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.